Kidney Cancer
FDA Approves Ensartinib in ALK-Positive NSCLC
The FDA has granted ensartinib approval for adult patients with ALK-positive non–small cell lung cancer.
Read More
Cancer Research Across Continents: Fujiwara’s Path From Japan to the US
In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.
Listen
Standard Belzutifan Dose Equally Effective as Higher Dose in ccRCC
In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating belzutifan for advanced clear cell renal cell carcinoma treatment.
FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC
In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
FDA Grants Breakthrough Status to Sacituzumab Tirumotecan in EGFR+ NSCLC
The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.
Participants Discuss Differences in Treatment in First-Line mRCC
During a Case-Based Roundtable® event, Daniel J. George, MD and participants discussed combination regimens for intermediate and poor-risk renal cell carcinoma.
